rapid-acting insulin product NovoLog, for the improvement of glycemic control in adults and children with diabetes mellitus. The FDA approved 3 mL single-patient-use prefilled pen and 10 mL ...

NovoLog is also available in pen injector formats. Before Merilog, the FDA has given the go-ahead to two biosimilars of Sanofi's basal insulin product Lantus (insulin glargine) – Viatris ...

The Food and Drug Administration (FDA) has approved Merilog (insulin-aspart-szjj), a biosimilar to Novolog (insulin aspart ... single-patient-use prefilled pen; the prefilled pen dials in ...

Merilog has been approved as biosimilar to Novolog (insulin aspart ... for both a 3 milliliter or mL single-patient-use prefilled pen and a 10 mL multiple-dose vial. As a rapid-acting human ...